DataMeds AI's Corexa Pharmacy Surpasses $1 Million In Monthly Revenue
Key Highlights
- ➤Corexa Pharmacy (MEDS) September revenue exceeded $1 million, preliminary and unaudited
- ➤September revenue increased more than 66% from July 2026 revenue
- ➤Health Lives Here mobile application launched with Corexa Pharmacy prescription fulfillment
- ➤Helomics acquisition opens potential demand for oncology medications and nutritional support products
Expert Statements
Gerald Commissiong, Interim Co-CEO of DataMEDS and CEO of Tollo Health
“Having completed the rebranding of Corexa Pharmacy in the first month of the third quarter of 2026, we are very pleased to already see such substantial growth so quickly”
Gerald Commissiong, Interim Co-CEO of DataMEDS and CEO of Tollo Health
“With the recent launch of Tollo Health's proprietary dietary supplements and medical foods combined with strong organic growth from our growing retail customer base, we are beginning to see the growth in both prescriptions filled and adjunct product sales.”
Gerald Commissiong, Interim Co-CEO of DataMEDS and CEO of Tollo Health
“We believe this represents the beginning of a growth cycle that will continue to accelerate as Corexa becomes known for dispensing and augmenting the patient experience for patients taking GLP-1 receptor agonist FDA-approved prescription drugs and the Long COVID community.”
Gerald Commissiong, Interim Co-CEO of DataMEDS and CEO of Tollo Health
“With the recent launch of the Health Lives Here mobile application that offers Corexa Pharmacy as a fulfillment option for telehealth prescriptions, combined with the closing of the Helomics Corporation acquisition that opens up potential demand for oncology-based medications and nutritional support products, we believe that Corexa Pharmacy is well positioned for future growth.”
Gerald Commissiong, Interim Co-CEO of DataMEDS and CEO of Tollo Health
“We are also in the process of upgrading the physical location of Corexa Pharmacy to serve as the flagship model for our Health Lives Here initiative with NFL Alumni Health.”
TAMPA, FL / ACCESS Newswire / October 1, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its artificial intelligence platform EinsteinRx(™) and smart contracts platform PharmacyChain(™), today provided a revenue update on Corexa Pharmacy, a division of its wholly owned subsidiary Corexa Health.
Corexa Pharmacy recorded preliminary, unaudited revenue of more than $1 million for September 2026, an increase of more than 66 percent from revenue reported for July 2026. (link) "Having completed the rebranding of Corexa Pharmacy in the first month of the third quarter of 2026, we are very pleased to already see such substantial growth so quickly," said Gerald Commissiong, Interim Co-CEO of DataMEDS. "With the recent launch of Tollo Health's proprietary dietary supplements and medical foods combined with strong organic growth from our growing retail customer base, we are beginning to see the growth in both prescriptions filled and adjunct product sales. We believe this represents the beginning of a growth cycle that will continue to accelerate as Corexa becomes known for dispensing and augmenting the patient experience for patients taking GLP-1 receptor agonist FDA-approved prescription drugs and the Long COVID community."
Get started
Create a free account to read the full story.